{
    "organizations": [],
    "uuid": "4852623202bb60713574e47eef477bf87e57fb52",
    "author": "",
    "url": "https://www.reuters.com/article/brief-celgene-says-bluebird-car-t-therap/brief-celgene-says-bluebird-car-t-therapy-remains-a-top-priority-idUSL2N1PK0UM",
    "ord_in_thread": 0,
    "title": "BRIEF-Celgene Says Bluebird Car-T Therapy Remains A Top Priority",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "January 25, 2018 / 3:05 PM / in 23 minutes BRIEF-Celgene Says Bluebird Car-T Therapy Remains A Top Priority Reuters Staff 1 Min Read \nJan 25 (Reuters) - Celgene Corp: \n* CELGENE CEO SAYS WORKING WITH BLUEBIRD BIO TO DEVELOP BB2121 CAR-T THERAPY FOR MYELOMA REMAINS A TOP PRIORITY \n* CELGENE CEO SAYS POSITIONED TO LAUNCH TWO CAR-T THERAPIES IN BLOOD CANCERS IN NEXT 3 YEARS \n* CELGENE SEES $1 BILLION SALES POTENTIAL FOR FEDRATINIB IN MYELOFIBROSIS, MID-2018 REGULATORY SUBMISSION Source text for Eikon: Further company coverage: (Reporting By Bill Berkrot)",
    "published": "2018-01-25T17:02:00.000+02:00",
    "crawled": "2018-01-25T17:35:58.003+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "january",
        "pm",
        "minute",
        "say",
        "bluebird",
        "therapy",
        "remains",
        "top",
        "priority",
        "reuters",
        "staff",
        "min",
        "read",
        "jan",
        "reuters",
        "celgene",
        "corp",
        "celgene",
        "ceo",
        "say",
        "working",
        "bluebird",
        "bio",
        "develop",
        "bb2121",
        "therapy",
        "myeloma",
        "remains",
        "top",
        "priority",
        "celgene",
        "ceo",
        "say",
        "positioned",
        "launch",
        "two",
        "therapy",
        "blood",
        "cancer",
        "next",
        "year",
        "celgene",
        "see",
        "billion",
        "sale",
        "potential",
        "fedratinib",
        "myelofibrosis",
        "regulatory",
        "submission",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "reporting",
        "bill",
        "berkrot"
    ]
}